Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0376358 (prostate cancer)
 59,338 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Because of an annual morbidity of 225,000 patients and mortality of over 56,000 patients per year in the United States from metastatic genitourinary malignancies, there is a great need for new systemic agents. With its activity and low toxicity, gemcitabine has begun to play a growing role in genitourinary cancer treatment and clinical trials. Substantial activity has been reported for gemcitabine combinations in the treatment of bladder cancer (median survival in one study of nearly 20 months) and for gemcitabine alone or in combinations in testicular cancer patients. Lower (but real) levels of activity have also been observed for gemcitabine combinations in renal carcinoma (17% response rate) and for monotherapy in hormone-refractory prostate cancer (7%). These data suggest the need for further trials of gemcitabine alone or in combinations in genitourinary cancer patients.
 ...
PMID:Future directions for gemcitabine in the treatment of genitourinary cancer. 1189 7

Prostate cancer, bladder cancer, renal cancer and testicular cancer are common among urological cancers. The treatment strategy for testicular cancer using chemotherapy has been well established and has been shown to be successful. Chemotherapy and radiotherapy play important roles in multidisciplinary therapy for bladder cancer. Radiotherapy is often used as a radical treatment that is practically equivalent to surgery for prostate cancer. In addition, radiotherapy is useful in cases of bone or brain metastases. In the field of chemotherapy, the development of new agents that would make breakthroughs similar to that of cisplatin is awaited. Taxanes and gemcitabine are good candidates. In the field of radiotherapy, 3D conformal radiation therapy (CRT), which has excellent beam distribution, has recently come into wide use. Moreover, brachytherapy and proton and ion beam therapy are expected to prove useful in prostate cancer therapy.
 ...
PMID:[Chemotherapy and radiotherapy for urological cancer]. 1204 Jun 74

Paclitaxel, a natural anticancer drug, has gained widespread acceptance as an active broad-spectrum antitumor agent, including its use in urological malignancies, particularly urothelial tract cancer and testicular cancer. The mechanism of action, based on the premature stabilization of the microtubule assembly with disruption of the cytoskeletal framework, is completely different from those of DNA-damaging agents, e.g., cisplatin and ifosfamide. As a single agent, paclitaxel is one of the most active drugs in metastatic bladder cancer, with an overall response rate of 40-50% being obtained in previously untreated patients. These promising single-agent results have prompted the use of combination regimens including, in particular, cisplatin and paclitaxel. A high degree of activity for the cisplatin-paclitaxel combination as reflected by responses in 50-80% of patients, including a substantial number of complete responses (> 30%), has been identified. The role of other agents such as vinorelbine, methotrexate, 5-fluorouracil, or ifosfamide as additions to this two-drug combination currently remains open. The combination of paclitaxel plus ifosfamide or vinorelbine in the absence of a platinum derivative has yielded rather disappointing results. Of particular interest may be the combination of paclitaxel and carboplatin. Both drugs can be given to patients with impaired renal function. Overall response rates of 45-60% have been reported in phase II studies. The so-called platelet-sparing effect of paclitaxel given in combination with carboplatin has resulted in a surprisingly low frequency of myelotoxicity, particularly thrombocytopenia. The combination of paclitaxel with carboplatin is being compared in an ongoing trial against the current standard MVAC regimen (methotrexate/vinblastine/Adriamycin/cisplatin) in patients with metastatic disease. Furthermore, the activity of paclitaxel-based combinations is currently being explored in the neoadjuvant setting in phase II studies, and the potential for the combination with the other new promising agent--gemcitabine--will be evaluated in a phase I setting. In prostate cancer, estramustine phosphate is widely used as palliative treatment for patients with hormone-refractory disease. In vitro synergistic activity has been observed between estramustine and paclitaxel in prostate-cancer cell lines, although paclitaxel has not demonstrated single-agent activity in patients with hormone-refractory prostate cancer. In clinical trials the combination of the two agents was associated with increased gastrointestinal toxicity. The addition of etoposide as a third drug has yielded prostate-specific antigen (PSA)-response rates of > 50%, but data on quality of life and survival time have not been reported for these combinations. A true clinical role for paclitaxel in prostate cancer has therefore not been established. Paclitaxel has finally demonstrated single-agent activity in relapsed and/or cisplatin-refractory testicular cancer in recent phase II trials, indicating different mechanisms of resistance to cisplatin and paclitaxel. These results have formed the rationale for the introduction of paclitaxel as part of combination chemotherapy regimens in patients with relapsed but chemosensitive testicular cancer. Preliminary results demonstrate that paclitaxel can be safely included into these conventional-dose combination regimens. When it is used prior to high-dose chemotherapy, sufficient numbers of peripheral blood stem cells (PBSCs) for high-dose therapy can be collected. The final role of paclitaxel in risk-adapted chemotherapeutic strategies in testicular cancer is not defined, but it appears that paclitaxel-based combinations can achieve a substantial response rate in patients with relapsed disease.
 ...
PMID:Recent strategies for the use of paclitaxel in the treatment of urological malignancies. 1207 32

There is increasing evidence that metabolic imaging with positron-emission tomography (PET) using fluor-18 labeled fluorodeoxyglucose (18F FDG) is highly accurate for in vivo detection of a variety of malignancies. This quality gives FDG-PET an important role in the detection of malignant tumors and their metastases as well as for differentiation of tumors of unknown etiology. In the male and female reproductive tract, whole body imaging with FDG-PET is in particular capable of visualizing lymph-node and distant metastases before these changes become apparent on conventional cross-sectional imaging modalities. According to the incidence of tumors in the reproductive tract, FDG-PET-imaging has been evaluated in prostate cancer, ovarian cancer, cervical and testicular cancer. The role of PET is discussed with respect to the current management of patients. The presented data indicate that FDG-PET is more accurate for lymph-node staging in cervical cancer and testicular cancer. In ovarian cancer, FDG-PET may be helpful for detection of tumor recurrence. The role of FDG-PET is questionable in prostate cancer, due to the low metabolic activity of this type of cancer. Carbon-11 labeled acetate and carbon-11 or fluor-18 labeled choline are more promising than FDG for detection of recurrence in prostate cancer. In all other tumors of the reproductive tract there is limited experience with PET for a final conclusion.
 ...
PMID:PET-imaging in tumors of the reproductive trac. 1211 73

Sexually transmitted diseases (STDs) threaten men's reproductive health, but they are preventable. When the means to prevent STDs are unknown, unavailable, unused, or fail, STDs can threaten the health and fertility of both men and their sex partners. Other threats, such as environmental toxins which may affect men's offspring or reduce sperm count and consequently fertility, have not been consistently identified. If these latter threats exist, they may be preventable. Other reproductive system conditions, such as prostate and testicular cancer, may or may not be preventable, but they pose no risk to others. Since the advent of AIDS, greater attention has been focused upon STDs as primary reproductive health threats. STDs, STD-related infertility, how male reproductive health status affects family health, environmental threats to male fertility, prostate cancer, and testicular cancer are discussed.
 ...
PMID:Men's reproductive health risks. 1229 37

In 1989, Pro-Pater, a private, nonprofit family planning organization in Brazil, used attractive ads with the message Vasectomy, An Act of Love to promote vasectomy. The number of vasectomies performed/day at Pro-Pater clinics increased from 11 to 20 during the publicity campaign and fell after the ads stopped but continued at higher levels. Word of mouth communication among friends, neighbors, and relatives who had vasectomies maintained these high levels. This type of communication reduced the fear that often involves vasectomies because men hear from men they know and trust that vasectomies are harmless and do not deprive them of potency. In Sao Paulo, the percentage of men familiar with vasectomies and how they are performed increased after the campaign, but in Salvador, knowledge did not increase even though the number of vasectomies in Pro-Pater clinics increased. Organizations in Colombia and Guatemala have also been effective in educating men about vasectomies. These successes were especially relevant in Latin American where machismo has been an obstacle of family planning programs. The no-scalpel technique 1st introduced in China in 1974 reduces the fear of vasectomy and has fewer complications than the conventional technique. Further trained physicians can perform the no-scalpel technique in about 10 minutes compared with 15 minutes for the conventional technique. In 1987 during a 1-day festival in Thailand, physicians averaged 57 no-scalpel vasectomies/day compared with only 33 for conventional vasectomies. This technique has not spread to Guatemala, Brazil, Colombia, the US, and some countries in Asia and Africa. Extensive research does not indicate that vasectomy has an increased risk of testicular cancer, prostate cancer, and myocardial infarction. Physicians are working on ways to improve vasectomy.
 ...
PMID:Making vasectomy attractive. 1231 26

We studied social class variation in the incidence of cancers of the prostate, testis, penis and scrotum among 1.1 million Finnish men (45-69 years of age) during 1971-95. The incidence of prostate cancer (6,972 cases) was increasing during the study period; the highest at all the times occurred in Social Class I (highest social class), 40-50% higher than in Social Class IV (lowest). The social class gradient was strongest in localized disease but there was some variation in incidence of non-localized prostate cancer. A total of 174 testicular cancer cases were diagnosed during the study period. In the early 1970s, the incidence of testicular cancer in Social Class I was 5-fold compared to Social Classes III and IV. Thereafter, the incidence rate decreased in Social Class I, but increased in the lower classes. The positive social class gradient was similar for seminomas and non-seminomas. For penile cancer (n = 128), the incidence decreased over time and social class variation was small. Only 6 cases of scrotum cancer were observed. In testicular cancer the strong positive social class association in the early 1970s is disappearing along with converging incidence trend slopes in different social classes. The difference diminished to less than 2-fold in the 1990s. Reasons for this observation remain open.
 ...
PMID:Socio-economic differences in incidence rates of cancers of the male genital organs in Finland, 1971-95. 1244 8

In Japan dramatic lifestyle changes occurred after World War 2. To examine the experience of Japan as a clue to the etiology, trends in the mortality rates of testicular and prostatic cancers from 1947 to 1998 were related to changes in dietary practices. The male population born before 1945 had a peak in death from testicular cancer in their thirties or forties, whereas those born after 1946 had a peak in their twenties. The death rate of prostatic cancer increased 25-fold almost linearly after the war. The intake of milk, meat, and eggs increased 20-, 9-, and 7-fold, respectively, after the war. In connection with the development and growth of testicular and prostatic cancers in Japan, particular attention should be paid to milk, because the increase in its consumption in this country is a recent occurrence and because milk contains considerable amounts of estrogens plus saturated fats.
 ...
PMID:The experience of Japan as a clue to the etiology of testicular and prostatic cancers. 1271 Sep 11

For urological tumours, positron emission tomography (PET) is currently most useful in testicular cancer. In patients with residual masses or raised marker levels after treatment, PET is both sensitive and specific for detecting recurrent disease, at suspected and unsuspected sites. Although fewer studies are available it also appears to be useful for staging at diagnosis, although this requires further investigation. Prostate cancer imaging has been more variable, with studies showing that PET cannot reliably differentiate between tumour and hypertrophy. It is not as good as a bone scan for defining bone metastases. In renal cancer, PET can be used to define the primary tumour, providing better staging of local recurrence than computed tomography (CT), and to define metastatic disease. There are few studies in bladder cancer, and despite excretion of the tracer via the bladder in early studies, it has better results than CT or magnetic resonance imaging for local staging; again it can detect metastases. Overall, the place of PET in urological tumours is developing, with the strongest areas undoubtedly being testicular and renal cancer. Tracers other than fluorodeoxyglucose are being examined and are providing further information.
 ...
PMID:Positron emission tomography for urological tumours. 1282 66

Prostate cancer, bladder cancer, renal cancer and testicular cancer are the most frequent malignancies in urology. Additional to parameters such as patient age, course of the disease, different forms of therapy and survival rates, quality of life is gaining more importance. This parameter is usually evaluated using general and disease-specific questionnaires. The SF-36 and the QLQ-C30 (EORTC) questionnaires are well established to determine quality of life in general. Disease-specific questionnaires for renal cancer and testicular cancer are currently under development. Bladder cancer can be evaluated by two EORTC modules investigating parameters such as voiding, bowel function and sexual function. The QLQ-BLS24 is made for patients with superficial bladder cancer and contains 24 questions. Also, side effects from intravesical therapy and repeated cystoscopies are determined. The QLQ-BLM30 is used for invasive bladder cancer. There are 30 questions to determine the impact of a urostoma (<<body image>>) or repeated catheterization. For prostate cancer many disease-specific questionnaires are available, however, only few are translated into German. One is the prostate cancer module QLQ-PR25 with 25 questions highlighting side effects (voiding, bowel function, sexual function) from prostatectomy, radiotherapy or antihormonal therapy. Despite problems when comparing different studies concerning quality of life in patients with localized prostate cancer one finds that radical prostatectomy is inferior in terms of continence, inferior or equal concerning sexual function and superior with respect to bowel function when compared with radiotherapy. It is noteworthy that there is no difference between prostatectomy and radiotherapy with respect to overall quality of life. Beside the development of disease-specific questionnaires, a future major issue is the standardized determination of the parameter quality of life to achieve a basis to compare the results of different studies.
 ...
PMID:[Quality of life in urologic oncology: new aspects]. 1460 54


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>